| Qian Niu,Jiamin Liu,Xiaoxiao Luo,Beibei Su,Xianglin Yuan. Future of targeted therapy for gastrointestinal cancer: Claudin 18.2. Oncol Transl Med, 2021, 7: 102-107. |
| Future of targeted therapy for gastrointestinal cancer: Claudin 18.2 |
| Received:November 16, 2020 Revised:June 22, 2021 |
| View Full Text View/Add Comment Download reader |
| KeyWord:gastrointestinal cancer; claudin 18.2 (CLDN18.2); targeted therapy; ideal monoclonal antibody 362 (IMAB362); chimeric antigen receptor (CAR) T cells treatment |
| Author Name | Affiliation | E-mail | | Qian Niu | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | 645020547@qq.com | | Jiamin Liu | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | | | Xiaoxiao Luo | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | | | Beibei Su | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | | | Xianglin Yuan | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | xlyuan1020@163.com |
|
| Hits: 3529 |
| Download times: 4389 |
| Abstract: |
| The treatment of gastrointestinal cancer has always been a crucial research area, and targeted therapy
has been receiving increasing attention. At present, the effect of targeted therapy is unsatisfactory for
gastric cancer. Thus, the discovery of new targets is crucial. Claudin 18.2 (CLDN18.2), a member of the
claudin family, belongs to the tight junction protein family that controls the flow of molecules between
cell layers. CLDN18.2 expression has been discussed in many studies. In recent years, there have been
many studies on targeted therapy with CLDN18.2-ideal monoclonal antibody 362. Furthermore, CLDN18.2-
specific chimeric antigen receptor T therapy has been used for CLDN18.2-positive tumors, such as gastric
and pancreatic cancers. Considerable research has been focused on CLDN18.2. CLDN18.2, a newly
discovered marker for precise targeted therapy of gastric cancer, could offer new hope for the treatment of
gastric cancer. |
| Close |
|
|
|